Physician profile
Anna Bunch
NPI 1336149459
$1,182.93
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $324 · 2022: $246 · 2023: $492 · 2024: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $297.88 | 2021-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $223.18 | 2021-2023 | Breztri |
| Mylan Specialty L.P. | $142.28 | 2021-2024 | Yupelri |
| Paratek Pharmaceuticals, INC. | $136.23 | 2021-2023 | Nuzyra |
| Jazz Pharmaceuticals INC. | $120.86 | 2022-2023 | |
| Harmony Biosciences LLC | $83.14 | 2023 | Wakix |
| Axsome Therapeutics, INC. | $73.54 | 2023 | Sunosi |
| Abbvie INC. | $44.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.41 | 2023 | Austedo |
| Emd Serono, INC. | $14.60 | 2023 | Mavenclad |
| Kyowa Kirin, INC. | $13.82 | 2023 | Nourianz |
| Lilly USA, LLC | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bunch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.